서브이미지

About Us

CEO Message

Genofocus is a company that develops new microbiome drugs, develops/produces industrial special enzymes using microbial metabolism.

Genofocus has platform technology required for economy of scale production for enzyme production, with respective technologies and facilities to maximize enzyme efficiency by improving host microorganism quickly and precisely.

Genofocus is developing and producing variety of industrial special enzymes based on core-technologies and accumulated know-hows.
Genofocus is taking a step further by developing next-generation microbiome new drugs.

대표이사 김의중

Eui Joong, Kim

CEO

Major history

  • PhD in Biotechnology at Yonsei University
    • Microbial surface display technology application (enzyme, antibody, vaccine, peptide) major
  • Chairman and planning secretary of Korea Bio-venture Industry Research Association
  • Affiliated professor of biotechnology at Soongsil University and Chonnam National Unviersity.
  • Genofocus, Inc. (CEO, former principal investigator)
  • GF fermentech, Inc. (Former CEO)

Jaegu, Pan

Founder & CTO

Major history

  • PhD in Biotechnology at KAIST
    • Enzyme and fermentation major
  • Postdoctoral of Bioprocess Bioengineering at Compiene College of Engineering (France)
  • Principal Investigator at Korea Research Institute of Bioscience and Biotechnology (KRIBB) for 34 years.
    • Director of Protein Industry Technology Center and Super Bacteria Research Center
    • Biodefence research.
    • First domestic microbial surface display technology inventor.
    • Super bacteria defense technology development
    • Mucosal research and vaccine
  • Genofocus, Inc. (CTO, former CEO)
  • Biomlogic, Inc. (CEO)

Taek-Ho Yang

Director of research institute.

  • KAIST's Ph.D. in Bioscience.
    • Microbial display and enzyme engineering major.
  • LG Chem research team leader.
    • Development of enzyme and biological conversion process.
  • GS Caltex Technology Research Institute.
    • Development of bio-chemical material production technology.

Won-Bae Kim

Chairman of the New Drug Advisory Committee.

  • Seoul National University, Ph.D. : Pharmacy
  • Dong-A ST CEO and Vice Chairman.
  • A member of the Presidential Advisory Committee on the Advancement of the Medical Industry.
  • National Science and Technology Commission Policy of the Ministry of Science and Technology. Expert committee member.
  • Regular member of the Korea Institute of Science and Technology.

Jeong-Hyun Kim

Senior researcher.

  • Doctor of Biotechnology at KAIST.
    • Molecular biology major.
  • Purdue University and Korea Research Institute of Biotechnology. Postdoc
  • Samyang Genex's lead researcher.
    • Development of medicinal protein
  • Inje University, Paik Hospital, professor of molecular biology.
    • Biopharmaceutical category.

In-Ik Jang

Director of Planning.

  • Doctor of Integrated Biology at UTSW Medical Center
  • Researcher at Samsung Life Science Research Institute.
  • Genentech, a postdoctoral researcher at UCSF.
  • Yonsei University Dental Research Professor.
  • Senior researcher at GNT Pharma.
  • Clinical progress control tower

Jeong-Jun Han

gffermentech CEO

  • Doctor of Biotechnology at KAIST.
    • Enzyme engineering, bio-conversion technology major.
  • Doosan R&D Center/ Doosan Glonet team leader.
    • Physiologically active lipid synthesis, separation, purification process. Development, planning, development of new functional bio materials, Production marketing.

Jong-Su Choi

gffermentech CEO

  • Daesang Co., Ltd. - Head of research team at the Central Research Institute.
  • Director of the Korea Bio Research Institute, BASF Korea.
    • Product production technology for bio materials.
  • Head of CJ CheilJedang Bio Research Institute (Sangmu)
    • Production strain and fermentation process development of biomaterials such as amino acids.